Advertisement
UK markets close in 7 hours 11 minutes

  • FTSE 100

    8,084.18
    +39.37 (+0.49%)
     

  • FTSE 250

    19,811.54
    +11.82 (+0.06%)
     

  • AIM

    756.34
    +1.47 (+0.19%)
     

  • GBP/EUR

    1.1628
    -0.0000 (-0.00%)
     

  • GBP/USD

    1.2431
    -0.0022 (-0.18%)
     

  • Bitcoin GBP

    53,521.20
    +346.64 (+0.65%)
     

  • CMC Crypto 200

    1,436.11
    +12.01 (+0.84%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    83.48
    +0.12 (+0.14%)
     

  • GOLD FUTURES

    2,331.90
    -10.20 (-0.44%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,176.31
    +347.38 (+2.06%)
     

  • DAX

    18,214.82
    +77.17 (+0.43%)
     

  • CAC 40

    8,121.09
    +15.31 (+0.19%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Hikma profit jumps on strong injectible drug sales

Reuters - UK Focus

March 11 (Reuters) - Hikma Pharmaceuticals Plc (LSE: HIK.L - news) reported a 21 percent rise in full-year pretax profit, helped by strong demand for its high-margin injectible drugs, particularly in the United States.

The Jordanian company, which makes and markets branded and non-branded generics and injectible drugs, also said it expected 2015 revenue growth of about 6 percent in constant currency terms.

Pretax profit rose to $362 million in the year ended Dec. 31, from $298 million a year earlier.

Revenue rose 9 percent to $1.49 billion. (Reporting by Roshni Menon in Bengaluru; Editing by Gopakumar Warrier)